The overexpression and/or mutations of epidermal growth factor receptor (EGFR) family proteins, i.e., EGFR (HER1), ERBB2, ERBB3 and ERBB4, are often found in multiple types of cancer cells and are considered to be a significant prognostic indicator in the clinical intervention of cancer. This evidence concerns the gene ERBB4 and cancer.